Table 4.
Univariate and multivariate analysis of OS.
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (≥65 vs <65 years) | 1.78 (1.14–2.78) | 0.01 | 1.62 (1.08–2.49) | 0.02 |
| Gender (male vs female) | 2.03 (1.30–3.18) | <0.01 | 2.17 (1.40–3.39) | <0.01 |
| Tumor location (head vs body/tail) | 1.98 (1.13–3.72) | 0.02 | 1.89 (1.07–3.57) | 0.03 |
| CEA (≥5 ng/mL vs <5 ng/mL) | 1.21 (0.73–1.96) | 0.44 | ||
| CA19–9 (≥100 U/mL vs <100 U/mL) | 1.10 (0.71–1.71) | 0.7 | ||
| Tumor size (≥20 mm vs <20 mm) | 1.27 (0.72–2.40) | 0.02 | 1.40 (0.81–2.56) | 0.24 |
| Peritoneal washing cytology (positive vs negative) | 1.25 (0.59–2.70) | 0.55 | ||
| Portal vein invasion (positive vs negative) | 1.76 (1.11–2.87) | 0.02 | 1.97 (1.25–3.16) | <0.01 |
| Perineural invasion (positive vs negative) | 1.74 (1.07–2.82) | 0.03 | 2.70 (1.11–8.23) | 0.04 |
| Lymph node metastasis (positive vs negative) | 2.52 (0.78–1.28) | 0.13 | ||
| UICC Stage IA/IB/IIA/IIB/IV | 1.58 (1.04–2.40) | 0.04 | 3.40 (1.65–7.02) | <0.01 |
| EMT (mesenchymal vs epithelial) | 4.20 (2.51–7.25) | <0.01 | 4.65 (2.78–8.01) | <0.01 |
| LOXL2 expression | 2.07 (1.14–3.96) | 0.02 | 1.87 (1.06–3.46) | 0.03 |
Abbreviations, CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; EMT, epithelial-to-mesenchymal transition; LOXL2, lysyl oxidase-like protein 2; HR, hazard ratio; CI, confidence interval.